Article 49 of the Dutch Medicines Act obliges marketing authorisation holders and manufacturers to report the availability on the market and supply interruptions of a medicinal product. The Medicine shortages and defects notification centre offers a central location for marketing authorisation holders and manufacturers to submit various notifications.
The Medicine shortages and defects notification centre is coordinated by the Medicines Evaluation Board (MEB) and the Health and Youth Care Inspectorate (IGJ).